Elevated serum levels of YKL-40 in GBM patients are positively correlated with tumor invasiveness, resistance to chemo/radiotherapy, and short survival, suggesting that YKL-40 serves as a prognostic biomarker for poorer clinical outcomes. The gene discussed is CHI3L1; the disease is glioblastoma.